James L. Elia

James L. Elia

Auto-generated profile, based on publicly available information

James L. Elia

Department of Pathology, Yale University, New Haven, CT, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2021 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
SFSTEFANO FEDELI
STEFANO FEDELI
JIJungkyun Im
Jungkyun Im
SGSanjana Gopalakrishnan
Sanjana Gopalakrishnan
JEJames L. Elia
James L. Elia
AGAarohi Gupta
Aarohi Gupta
Vincent M. RotelloVincent M. Rotello
Vincent M. Rotello
Bioorthogonal transformations are chemical reactions that use pathways which biological processes do not access. Bioorthogonal chemistry provides new approaches for imaging and therapeutic strategies, as well as tools for fundamental biology. Bioorthogonal catalysis enables the development of bioorthogonal “factories” for on-demand and in situ generation of drugs and imaging tools. Transition metal catalysts (TMCs) are widely employed as bioorthogonal catalysts due to their high efficiency and versatility. The direct application of TMCs in living systems is challenging, however, due to their limited solubility, instability in biological media and toxicity. Incorporation of TMCs into nanomaterial scaffolds can be used to enhance aqueous solubility, improve long-term stability in biological environment and minimize cytotoxicity. These nanomaterial platforms can be engineered for biomedical applications, increasing cellular uptake, directing biodistribution, and enabling active targeting. This review summarizes strategies for incorporating TMCs into nanomaterial scaffolds, demonstrating the potential and challenges of moving bioorthogonal nanocatalysts and nanozymes toward the clinic.

18 April 2022 in ACS Nano
Verified
Journal Article
Closed access
DLDavid C. Luther
David C. Luther
YLYi-Wei Lee
Yi-Wei Lee
HNHarini Nagaraj
Harini Nagaraj
VCVincent Clark
Vincent Clark
TJTaewon Jeon
Taewon Jeon
Vincent M. RotelloVincent M. Rotello
Vincent M. Rotello

30 May 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
EHEric D. Huseman
Eric D. Huseman
ALAnna Lo
Anna Lo
OFOlga Fedorova
Olga Fedorova
JEJames L. Elia
James L. Elia
SGSusan E. Gueble
Susan E. Gueble
SHSeth B. Herzon
Seth B. Herzon

2 July 2026 in Bioinformatics
Verified
Journal Article
Open access
JEJames L Elia
James L Elia
SFSam Friedman
Sam Friedman
RBRanjit Bindra
Ranjit Bindra
Summary: Nuclei counting provides a low-cost, metabolic-independent alternative to ATP- or tetrazolium-based cell viability assays. However, the fragmentation of image processing, normalization, and statistical modeling across multiple software platforms hinders high-throughput adoption. We present CellPyAbility, a Python-based suite that automates image processing, dose-response fitting, and synergy analysis. It converts unedited whole-well images into publication-ready graphics in under 1 minute per 96-well plate on standard desktop hardware. Availability and implementation: CellPyAbility is open-source (MIT License) and available as a Python package via PyPI and Bioconda, or as a code-free application for macOS and Windows. Source code and documentation are available at https://github.com/bindralab/cellpyability and on Zenodo at https://doi.org/10.5281/zenodo.20693745.

9 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JEJames L. Elia
James L. Elia
JHJarvis Hill
Jarvis Hill
CHCollin D. Heer
Collin D. Heer
SSSiji Smolev
Siji Smolev
ASAbbey M. Sykes
Abbey M. Sykes
RBRanjit Bindra
Ranjit Bindra
A bstract: Homologous recombination deficiency (HRD) is an actionable vulnerability found in a substantial fraction of human cancers, yet current HRD-directed therapies are limited by toxicity, incomplete responses, and acquired resistance. Many DNA-damaging agents were developed before DNA repair biomarkers were available, suggesting that abandoned agents may harbor previously unrecognized genotype-selective activity. Here, through a focused screen of DNA-damaging agents in isogenic homologous recombination-proficient and -deficient models, we identify CB1954, a decades-old nitrobenzamide aziridine prodrug, as highly selective for BRCA2-deficient tumor cells. CB1954 forms DNA interstrand crosslinks independent of HR status, but selectively induces DNA-damage signaling, apoptosis, and loss of clonogenic survival in HR-deficient cells. Targeted DDR CRISPR screening and isogenic validation define a distinct repair dependency for the Fanconi anemia and homologous recombination pathways, with limited dependence on mismatch repair or nucleotide excision repair. Genetic and pharmacologic perturbation of NQO2, the bioactivating enzyme for CB1954, reveals a bifurcated mechanism in which NQO2-dependent activation selectively contributes to HRD cytotoxicity, while aziridine-dependent lesions likely account for residual activity in HR-proficient cells. CB1954 exhibits favorable preclinical pharmacokinetic properties and genotype-dependent antitumor activity in BRCA2-deficient xenografts. These findings reposition CB1954 as a historically overlooked HRD-selective agent and demonstrate that biomarker-guided profiling of DNA-damaging agents can uncover new opportunities for precision oncology.